OFFICAL PROJECT SITE
Novel Target for Treatment of Chronic Inflammatory Diseases — Notid
A milestone has been reached
After an intensive and targeted work, the cell line development of our lead drug candidate SOL-116 has been finalized. Now the production optimization and scale up has been initiated and that will provide access of non-GMP and GMP material during 2020. That will enable toxicity studies and start of clinical [...]
Professor Anders Fasth joins the scientific advisory board
Press release November 29, 2019 Lipum has developed a biological drug candidate for treatment of chronic inflammatory diseases and aim for a better treatment of juvenile idiopathic arthritis (JIA), that affects children. Therefore, the scientific advisory board of the company is now strengthened with Anders Fasth, senior professor of pediatric [...]
Pharma Outsourcing 2019
“How we selected our CMO partner for cell line and production development of Lipum´s lead candidate drug SOL-116” […]
BioStock Life Science Summit
Life Science industry leaders, financing experts and qualified investors gather in Lund. Welcome to meet us at Biostock Life Science Summit, october 23th-24th. […]
Lipum participates in investment and partnering meeting
Today, our COO, Pernilla Abrahamsson, is traveling to Paris to participate at French-Swedish Life Science Days 2019. The goal of the conference is to establish new contacts and identify business and collaboration opportunities. The conference will gather early stage and highly innovative medtech and biotech companies from Sweden and France, [...]
Lipum to Basel for one-to-one meetings
- We are looking forward to one-to-one meetings in Basel, among the largest biopharma hubs in Europe, says CEO Einar Pontén when Lipum is preparing to participate at the 19th Annual Biotech in Europe Forum (Sachs) on September 25-26.
Program:
European Commission Horizon 2020
SME Instrument phase 1 No 744248
SME Instrument phase 2 No 829741
Project title:
Novel Target for Treatment of Chronic Inflammatory Diseases
Project budget:
3.2 M€
Funding from the EU:
2.2 M€
Start:
2018-11-01
End:
2020-11-30